Dendritic cell immunotherapy: mapping the way.
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.
Figdor
Carl G
CG
Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen, PO Box 9101, 6500HB Nijmegen, The Netherlands. c.figdor@ncmls.kun.nl
de Vries
I Jolanda M
IJ
Lesterhuis
W Joost
WJ
Melief
Cornelis J M
CJ
D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy; D019496:Cancer Vaccines / Q000302:isolation & purification / Q000592:standards; D002986:Clinical Trials as Topic / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007167:Immunotherapy / Q000379:methods*; D066298:In Vitro Techniques; D009369:Neoplasms / Q000276:immunology / Q000628:therapy
D000941:Antigens; D019496:Cancer Vaccines